Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Parasitic Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43925   clinical trials with a EudraCT protocol, of which   7306   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Parasitic Disease. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-001999-20 Sponsor Protocol Number: RD.03.SPR.40027 Start Date*: 2006-10-10
    Sponsor Name:Galderma Research & Development SNC
    Full Title: ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (RO...
    Medical condition: Patients with papulo-pustular rosacea
    Disease: Version SOC Term Classification Code Term Level
    9.0 10039218 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001226-42 Sponsor Protocol Number: MEBENDAZOLGAI3002 Start Date*: 2015-04-09
    Sponsor Name:Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Full Title: An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive
    Medical condition: Soil-transmitted helminth (STH) infections
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10063126 Worms LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003789-21 Sponsor Protocol Number: MULTBENZ Start Date*: 2017-01-11
    Sponsor Name:Fundación Hospital Universitari Vall d'Hebron - Institut de Recerca
    Full Title: Phase II trial for assessing different benznidazol regimens in the treatment of Chagas disease in adult patients on chronic phase . BERINECE project
    Medical condition: Chagas Disease on chronic phase
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10008384 Chagas' disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-005008-24 Sponsor Protocol Number: 08126 Start Date*: 2011-07-07
    Sponsor Name:University of Nottingham
    Full Title: Worms for immune regulation of multiple sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    13.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024657-36 Sponsor Protocol Number: DSR-01 Start Date*: 2011-05-17
    Sponsor Name:Statens Serum Institut
    Full Title: Metronidazol for the treatment of dientamoebiasis in children in Denmark – A randomized, placebo-controlled, double-blinded clinical trial.
    Medical condition: Presumed symptomatic gastrointestinal infection with the protozoan Dientamoeba fragilis.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10006051 Bowel dysfunction LLT
    13.1 10017947 - Gastrointestinal disorders 10016766 Flatulence PT
    13.1 10021881 - Infections and infestations 10021907 Infectious diarrhea LLT
    13.1 10017947 - Gastrointestinal disorders 10034453 Perianal itching LLT
    13.1 10017947 - Gastrointestinal disorders 10017999 Gastrointestinal pain PT
    13.1 10027433 - Metabolism and nutrition disorders 10016165 Failure to thrive PT
    13.1 10021881 - Infections and infestations 10067720 Parasitic gastroenteritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002645-38 Sponsor Protocol Number: BIOMARCHA Start Date*: 2012-09-04
    Sponsor Name:CRESIB-Barcelona Centre for International Health Research
    Full Title: Evolution of serologic biomarkers and diastolic function and segmentary contractility determined by echocardiography after treatment in Chagas diseases
    Medical condition: The study will be held in 63 patients with chronic Chagas Disease and 63 healthy people
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000161-36 Sponsor Protocol Number: P05267(MK-5592-055) Start Date*: 2013-07-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.,
    Full Title: Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267)
    Medical condition: Chronic Chagas Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004862 10066500 Chagas disease recurrent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-003156-37 Sponsor Protocol Number: RD.03.SPR.40037 Start Date*: 2006-10-13
    Sponsor Name:Galderma Research and Development SNC
    Full Title: AN EXPLORATORY STUDY TO EVALUATE RELAPSES FOLLOWING AN INITIAL 12 WEEKS DOSE-RANGE STUDY WITH CD5024 CREAM VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM IN PAPULO-PUSTULAR ROSACEA – A 6 M...
    Medical condition: Subject who was successfully treated for his/her papulo-pustular rosacea in the initial study (Galderma Study: Eudract N°: 2006-001999-20/RD.03.SPR.40027)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039218 Rosacea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000838-39 Sponsor Protocol Number: MHE104317 Start Date*: 2007-10-11
    Sponsor Name:GlaxoSmithKline Resaearch and Development Ltd
    Full Title: A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome
    Medical condition: Hypereosinophilic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NO (Completed) BE (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) PL (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003854-13 Sponsor Protocol Number: RD.03.SPR.40053 Start Date*: 2009-01-15
    Sponsor Name:GALDERMA R&D SNC
    Full Title: AN INVESTIGATOR BLIND PARALLEL GROUP VEHICLE CONTROL STUDY COMPARING THE EFFICACY AND SAFETY OF CD 5024 1% CREAM WITH METRONIDAZOLE 0.75% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 1...
    Medical condition: PAPULOPUSTULAR ROSACEA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039218 Rosacea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-004143-27 Sponsor Protocol Number: STRONG-FIX Start Date*: 2023-09-14
    Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
    Full Title: Randomized non-inferiority clinical trial to evaluate the efficacy of a single fixed dose of 18 mg ivermectin for the treatment of uncomplicated strongyloidiasis
    Medical condition: Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointes...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10042254 Strongyloidiasis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002900-34 Sponsor Protocol Number: CINE-BENZ Start Date*: 2012-03-07
    Sponsor Name:CRESIB- International Research Center in Health of Barcelona
    Full Title: Population Pharmacokinetics in Benznidazol-treated adults with Chronic Chagas Disease. Benznidazol Pharmacokinetics and adverse reactions relationship.
    Medical condition: The study will be held in 50 patients with Chronic Chagas Disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008384 Chagas' disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001504-17 Sponsor Protocol Number: 16027 Start Date*: 2022-04-08
    Sponsor Name:Bayer AG
    Full Title: Prospective, historically controlled study to evaluate the efficacy and safety of a new pediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas’ disease
    Medical condition: Chagas disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10008384 Chagas' disease LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002022-41 Sponsor Protocol Number: CHAGAS-EVOL I Start Date*: 2011-10-13
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Ramón y Cajal
    Full Title: Assessment of Therapeutic Response to Benznidazole in patients with Chronic Chagas Disease by Measuring Plasma Parasite Load and the Specific Immune Response against Trypanosoma cruzi. A Randomized...
    Medical condition: Chagas disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008384 Chagas' disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000301-71 Sponsor Protocol Number: TJB1117P1 Start Date*: 2013-01-25
    Sponsor Name:CHU-ULg
    Full Title: Donor Regulatory T cells (Treg) infusion (DTI) in patients with steroid-refractory chronic graft-versus-host disease (GVHD).
    Medical condition: Steroid-refractory chronic graft-versus-host-disease.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004905-15 Sponsor Protocol Number: DNDi-FEX-12-CH Start Date*: 2017-09-13
    Sponsor Name:Drugs for Neglected Diseases initiative (DNDi)
    Full Title: Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients with Chronic Indeterminate Chagas Disease
    Medical condition: Chagas disease (CD) is a disease caused by Trypanosoma cruzi, ranking among the world’s most neglected diseases. There is significant associated morbidity and mortality, particularly in chronic ph...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-003014-12 Sponsor Protocol Number: COPERNICOS_JUJCPR Start Date*: 2021-03-19
    Sponsor Name:Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)
    Full Title: COPD - Eosinophil-guided Reduction of Inhaled COrticoSteroids (COPERnICOS)
    Medical condition: Clinicaltrial on eosinophil-guided time-updated person-specific reduction of inhaled corticosteroid therapy and prophylactic azithromycin therapy in patients with severe or very severe chronic obst...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004416-66 Sponsor Protocol Number: VAC052 Start Date*: 2012-11-26
    Sponsor Name:University of Oxford
    Full Title: A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches using the ChAd63 and MVA vectors encoding the antigens ME-TRAP, CS and AMA1.
    Medical condition: Plasmodium falciparum Infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000393-30 Sponsor Protocol Number: VAC055 Start Date*: 2013-05-22
    Sponsor Name:University of Oxford
    Full Title: A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA encoding ME-TRAP and also ...
    Medical condition: Plasmodium falciparum infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005409-38 Sponsor Protocol Number: TriSulfa-FPI-1 Start Date*: 2013-04-19
    Sponsor Name:Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)
    Full Title: Pilot study phase III to evaluate the efficacy and safety of Trimethoprim-sulfamethoxazole in the treatment of idiopathic pulmonary fibrosis
    Medical condition: Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 17 18:19:19 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA